Kinase inhibitor compounds

1. A compound of formula II:

or a salt thereof; wherein:

R 1 is arylalkyl or heteroarylalkyl, each optionally substituted with 1-4 independent Z 1 ;

R 2 is C 6 -C 14 aryl, 5-12 membered heteroaryl, 3-15 membered heterocyclyl or amide, each optionally substituted with 1-4 independent Z 2 ;

R 3 is hydrogen, hydroxyl, alkoxy, or alkylamino;

R 5 is NH 2 ;

Each Z 1 and Z 2 is independently halogen, CN, NO 2 , OR 15 , SR 15 , S(O) 2 OR 15 , NR 15 R 16 , C 1 -C 2 perfluoroalkyl, C 1 -C 2 perfluoroalkoxy, 1,2-methylenedioxy, C(O)OR 15 , C(O)NR 15 R 16 , OC(O)NR 15 R 16 , NR 15 C(O)NR 15 R 16 , C(NR 16 )NR 15 R 16 , NR 15 C(NR 16 )NR 15 R 16 , S(O) 2 NR 15 R 16 , R 17 , C(O)R 17 , NR 15 C(O)R 17 , S(O)R 17 , S(O) 2 R 17 , R 16 , oxo, C(O)R 16 , C(O)(CH 2 )nOH, (CH 2 )nOR 15 , (CH 2 )nC(O)NR 15 R 16 , NR 15 S(O) 2 R 17 , where n is independently 0-6 inclusive;

Each R 15 is independently hydrogen, C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl;

Each R 16 is independently hydrogen, C 2 -C 10 alkenyl, C 2 -C 10 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 3-15 membered heterocyclyl, 5-12 membered heteroaryl, C 1 -C 4 alkyl or C 1 -C 4 alkyl substituted with C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 3-15 membered heterocyclyl or 5-12 membered heteroaryl; and

Each R 17 is independently C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 3-15 membered heterocyclyl, 5-12 membered heteroaryl, C 1 -C 4 alkyl or C 1 -C 4 alkyl substituted with C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 3-15 membered heterocyclyl or 5-12 membered heteroaryl.

2. The compound of claim 1 , wherein the compound is of Formula (IIa):

3. The compound of claim 1 , wherein the compound is of

Wherein R 6 and R 7 are independently hydrogen, optionally substituted C 1 -C 4 alkyl, C 6 -C 14 aryl, 5-12 membered heteroaryl, 3-15 membered heterocyclyl, and R 6 and R 7 together with the nitrogen they are attached to form an optionally substituted 3-15 membered heterocycle with 0-3 additional heteroatoms.

4. The compound of claim 1 , wherein R 3 is H.

5. The compound of claim 1 , wherein R 2 is 3-15 membered heterocycle optionally substituted with 1-4 independent Z 2 .

6. The compound of claim 1 , wherein the compound is one

(4-{6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazin-3-yl}-phenyl)-morpholin-4-yl-methanone;

(4-{6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazin-3-yl}-phenyl)-(4-methyl-piperazin-1-yl)-methanone;

(4-{6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazin-3-yl}-phenyl)-piperazin-1-yl-methanone;

4-{6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazin-3-yl}-N-(2-diethylamino-ethyl)-benzamide;

4-{6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazin-3-yl}-N,N-dimethyl-benzamide;

(4-{6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazin-3-yl}-phenyl)-(4-morpholin-4-yl-piperidin-1-yl)-methanone;

4-[1-(2,6-Dichloro-3-fluoro-phenyl)ethoxy]-6-pyrimidin-5-yl-pyridazin-3-ylamine;

4-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-6-[1-(tetrahydro-pyran-4-yl)-1H-pyrazol-4-yl]-pyridazin-3-ylamine;

4-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-6-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridazin-3-ylamine;

4-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-6-(6-morpholin-4-yl-pyridin-3-yl)-pyridazin-3-ylamine;

4-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-6-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-pyridazin-3-ylamine;

4-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-6-[4-(4-methyl-piperazin-1-yl)-phenyl]-pyridazin-3-ylamine;

6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazine-3-carboxylic acid pyridin-4-ylamide;

6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazine-3-carboxylic acid methylamide;

6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazine-3-carboxylic acid (tetrahydro-pyran-4-yl)-amide;

6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazine-3-carboxylic acid pyridin-3-ylamide;

6-Amino-5-[1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-pyridazine-3-carboxylic acid pyrimidin-5-ylamide.